Investigating the roles of YAP and TAZ in melanoma progression
Official title: The shared and distinct cistromes of YAP and TAZ in melanoma
Funded at Boston University Medical Campus · NIH-11035359 · Data updated 2026-11-12
This study is looking at how two proteins, YAP and TAZ, play a role in the growth and spread of melanoma, a type of skin cancer, to help find better ways to treat it.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Boston University Medical Campus NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | December 1, 2024 |
| Project end | November 30, 2026 |
| Funding year | 2025 |
| Award (this year) | $81,750 |
| NIH project number | 1R03CA288281-01A1 |
| Project ID | NIH-11035359 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with melanoma, particularly those with advanced or metastatic disease.
✕Less likely to help
Patients with non-melanoma skin cancers or early-stage melanoma may not benefit from this research.
What this research studies
This research focuses on understanding how two proteins, YAP and TAZ, contribute to the progression and spread of melanoma, a serious form of skin cancer. The researchers aim to identify the unique and shared functions of these proteins in cancer cells, particularly how they affect cell growth and movement. By conducting detailed genetic analyses, they will explore how YAP and TAZ interact with other factors to influence cancer behavior. This could lead to new insights into melanoma treatment strategies.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic targets for treating melanoma, potentially improving patient outcomes.
How similar studies have gone: Previous research has shown that targeting specific molecular pathways in cancer can lead to significant advancements in treatment, suggesting potential success for this approach.
Where this research is happening
-
Boston University Medical Campus
Boston, United States Active
Researchers
- Principal investigator: Lang, Deborah — Boston University Medical Campus
- Study coordinator: Lang, Deborah
Related research
Other NIH-funded projects on the same topics.
-
Melanoma vaccine built from tiny spherical nucleic acids
A new kind of cancer vaccine using tiny spherical nucleic acids to help the immune system fight advanced melanoma.
-
Injecting immune-boosting medicine into melanoma tumors to help the immune system reject them
This gives an immune-boosting drug directly into melanoma tumors in pet dogs to help their T cells find and destroy the cancer.
-
SIRT6 and melanoma growth and spread
Researchers are seeing if blocking a protein called SIRT6 can help stop melanoma from growing and spreading in people with melanoma.
-
How tumor cell stress and nearby support cells help melanoma spread
This project looks at whether blocking a tumor cell stress response and changing how nearby support cells behave might keep melanoma cells from surviving, spreading, and resisting treatment.
-
PLK4 as a potential drug target in melanoma
Researchers are exploring whether blocking PLK4 could be a new way to treat melanoma and how PLK4 works with other melanoma-driving pathways.
-
A new lentivector to deliver multiple TCRs for melanoma cell therapy
A new gene-delivery approach aims to boost T cell receptors inside patients’ own cells to treat advanced melanoma.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.